Publications by authors named "D Frankhouser"
Article Synopsis
- The study investigates the effects of dietary n-3 polyunsaturated fatty acids (EPA and DHA) on women with estrogen receptor and progesterone receptor-negative (ERPR-) breast cancer over a 12-month period.
- Participants received either 1g/d or 5g/d of EPA+DHA supplementation, with results indicating that the higher dosage was more effective in increasing n-3 PUFAs and reducing plasma triglycerides.
- The research also identified distinct DNA methylation patterns in adipose tissue linked to the 5g/d dosage, suggesting significant metabolic and molecular changes associated with higher n-3 fatty acid intake.
Acute myeloid leukemia (AML) is prevalent in both adult and pediatric patients. Despite advances in patient categorization, the heterogeneity of AML remains a challenge. Recent studies have explored the use of gene expression data to enhance AML diagnosis and prognosis, however, alternative approaches rooted in physics and chemistry may provide another level of insight into AML transformation.
View Article and Find Full Text PDFTrastuzumab therapy in HER2+ breast cancer patients has mixed success owing to acquired resistance to therapy. A detailed understanding of downstream molecular cascades resulting from trastuzumab resistance is yet to emerge. In this study, we investigate the cellular mechanisms underlying acquired resistance using trastuzumab-sensitive and -resistant cancer cells (BT474 and BT474R) treated with endogenous ligands EGF and HRG across time.
View Article and Find Full Text PDFArticle Synopsis
- - Chronic myeloid leukemia (CML) is driven by the BCR::ABL gene, and while treatment with tyrosine kinase inhibitors (TKIs) can lead to long-term remission, it doesn’t cure the disease.
- - Researchers studied blood samples from mice with CML to develop a state-transition model based on gene expression, identifying critical disease stages and the role of certain genes in CML progression.
- - The study found that silencing the BCR::ABL gene could improve transcriptomes towards a healthier state, but some changes are irreversible, and TKIs can only lead to temporary improvements, emphasizing the need for timely clinical interventions.
Chronic myeloid leukemia (CML) is initiated and maintained by BCR::ABL which is clinically targeted using tyrosine kinase inhibitors (TKIs). TKIs can induce long-term remission but are also not curative. Thus, CML is an ideal system to test our hypothesis that transcriptome-based state-transition models accurately predict cancer evolution and treatment response.
View Article and Find Full Text PDF